Details of the Drug

General Information of Drug (ID: DM7QUN0)

• Drug Name: HQK-1001
• Synonyms: Sodium ST-20; Hematological disease therapeutic (oral), HemaQuest

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Phase 2	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 138.14
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 2
  Hydrogen Bond Donor Count; 0
  Hydrogen Bond Acceptor Count; 2
• Chemical Identifiers:
  Formula: C6H11NaO2
  IUPAC Name: sodium;2,2-dimethylbutanoate
  Canonical SMILES: CCC(C)(C)C(=O)[O-].[Na+]
  InChI: InChI=1S/C6H12O2.Na/c1-4-6(2,3)5(7)8;/h4H2,1-3H3,(H,7,8);/q;+1/p-1
  InChIKey: OOPXYEYPPHJHSE-UHFFFAOYSA-M
• Cross-matching ID:
  PubChem CID: 53247304
  CAS Number: 3934-02-9
  TTD ID: D0E6SB

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Inducer	[2]

References

• [1] A phase 2 trial of HQK-1001 in HbE-beta thalassemia demonstrates HbF induction and reduced anemia. Blood. 2014 Mar 20;123(12):1956-7.
• [2] A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.